{"title":"Lancet Oncol 2024; 25: 1188-201 更正","authors":"","doi":"10.1016/s1470-2045(24)00635-1","DOIUrl":null,"url":null,"abstract":"<em>Karpinski MJ, Hüsing J, Claassen K, et al Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study.</em> Lancet Oncol <em>2024;</em> 25: <em>1188–201</em>—The appendix of this Article has been corrected as of Oct 30, 2024.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"87 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Oncol 2024; 25: 1188–201\",\"authors\":\"\",\"doi\":\"10.1016/s1470-2045(24)00635-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<em>Karpinski MJ, Hüsing J, Claassen K, et al Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study.</em> Lancet Oncol <em>2024;</em> 25: <em>1188–201</em>—The appendix of this Article has been corrected as of Oct 30, 2024.\",\"PeriodicalId\":22865,\"journal\":{\"name\":\"The Lancet Oncology\",\"volume\":\"87 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s1470-2045(24)00635-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(24)00635-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Karpinski MJ, Hüsing J, Claassen K, et al Combining PSMA-PET and PROMISE to redefine disease stage and risk in patients with prostate cancer: a multicentre retrospective study.Lancet Oncol 2024; 25: 1188-201-本文附录已于2024年10月30日更正。
Karpinski MJ, Hüsing J, Claassen K, et al Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study. Lancet Oncol 2024; 25: 1188–201—The appendix of this Article has been corrected as of Oct 30, 2024.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
